Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

Key Findings

• ●Confirms imatinib ineffective in D816V+ SM
• ●May benefit occasional D816V-negative patients

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works